RHS & Monash IVF Lead the Field in Non-Invasive Embryo Screening (Bioshares)
Nov 17, 2017 -
Bioshares - 10 November 2017, Edition 721
RHS (RHS: $0.125) is working in the field of reproductive medicine, and more specifically, pre-implantation genetic screening of embryos in IVF procedures.
While it has been struggling to take market share away from the major established players, it is working on a ground-breaking technology with Monash IVF that may allow non-invasive screening of embryos for correct chromosome number detection. It is also releasing a next generation sequencing (NGS) product that will allow it to better compete against its larger competitors.
At the American Society of Reproductive Medicine meeting in San Antonio last week, RHS's partner, Monash IVF (Repromed), presented data on non-invasive pre-implantation genetic screening. The results showed a very high correlation with the current approach, which takes a biopsy of the embryo.